Piedmont Hospital Named 2009 Most Wired Hospital for Sixth Consecutive Year

Piedmont Hospital has been named one of the nation’s Most Wired hospitals, according to the results of the 2009 Most Wired Survey and Benchmarking Study released in the July issue of Hospitals & Health Networks magazine. Three of the five Georgia hospitals named to the list are part of the Piedmont Healthcare system.

Piedmont Hospital has been named for six consecutive years, while Piedmont Fayette Hospital, also a winner this year, has been recognized for five consecutive years. Both hospitals are the only two in the metro Atlanta area to be named to the 2009 list. This is the second year for Piedmont Mountainside Hospital in Jasper, Ga., to be named in the small and rural category.

“We are proud the Most Wired Survey and Benchmarking Study has recognized Piedmont Hospital for the sixth year in a row as a Most Wired hospital,” said Robert Maynard, president and CEO of Piedmont Hospital. “This recognition shows our dedication to quality and excellence in the use of information technology to improve patient care and safety.”

The Most Wired Survey is conducted annually by Hospitals & Health Networks magazine, the journal of the American Hospital Association, which uses the results to name the 100 Most Wired hospitals and health systems. It focuses on how the nation’s hospitals use information technologies for quality, customer service, public health and safety, business processes and workforce issues.

“The economic slowdown is forcing hospitals to look closely at IT spending,” says Alden Solovy, executive editor of Hospitals & Health Networks magazine. “Most Wired hospitals are doing their best to stay the course.”

To complicate matters, the great unknown of healthcare reform looms in the near future and a number of regulatory changes are already heading down the pike, including the shift to ICD-10, which hospitals use to code the signs, symptoms and causes of injury or diseases.

“As the health reform debate continues, it’s clear that IT will play an even more important role in the health system of tomorrow,” says Rich Umbdenstock, president and CEO of the American Hospital Association (AHA). “Most Wired hospitals help illustrate IT in action—improving efficiency, quality and safety of care while helping to control costs.”

Hospitals also continue to invest in IT that supports quality and safety initiatives. Investment in electronic medication management is considered one of the fundamentals of using IT to improve care. The 2009 Most Wired Survey and Benchmarking Study shows an overall increase in both provider order entry of medications and electronic bedside matching at the time medications are administered.

Hospitals & Health Networks conducted the 2009 survey in cooperation with McKesson Corp. and the College of Healthcare Information Management Executives. The July H&HN cover story detailing results is available at www.hhnmag.com.
---
Community News You Can Use
Follow us on Twitter: @gafrontpage
www.FayetteFrontPage.com
www.GeorgiaFrontPage.com
www.PoliticalPotluck.com
www.ArtsAcrossGeorgia.com
---

Thoratec Corporation Issues Worldwide Medical Device Correction of HeartMate II® Left Ventricular Assist System

Thoratec Corporation is initiating a worldwide medical device correction of all serial numbers of the HeartMate II Left Ventricular Assist Systems (HM II LVAS) having Catalogue No. 1355 or 102139, which have been distributed since the beginning of clinical studies in November 2003. Over time, wear and fatigue of the percutaneous lead connecting the HeartMate II LVAS blood pump with the System Controller may result in damage that could interrupt pump function, require reoperation to replace the pump and potentially result in serious injury or death. The estimated probability of the need for pump replacement due to percutaneous lead damage is 1.3% at 12 months, 6.5% at 24 months and 11.4% at 36 months.

Patients who are currently being supported by a HeartMate II LVAS should contact their doctors, who can assess the wear and fatigue of the percutaneous lead as well as provide proper instruction on management and care of the lead.

Thoratec is voluntarily issuing an Urgent Medical Device Correction notice after confirming 27 reports where wear and fatigue to the percutaneous lead necessitated pump replacement. These reports occurred over five years of clinical experience with 1,972 implants. All patients who have undergone a replacement of the HeartMate II pump survived the operation and were alive at least 30 days postoperatively. In five cases, pump replacement was not feasible and the patients expired.

The affected systems were distributed to 153 hospitals and distributors throughout the United States, Europe, Canada and other countries. The HM II LVAS can be identified by the catalogue number located on the label of the package.

Hospitals are being sent an Urgent Medical Device Correction letter identifying the probability and symptoms of the problem, and recommending that the pump be replaced as soon as possible if damage to the percutaneous lead is confirmed. Hospitals are also requested to review the instructions for care of the percutaneous lead with their ongoing HeartMate II LVAS patients. Hospitals with ongoing HeartMate II LVAS patients should contact Thoratec for further instructions if they do not receive the Medical Device Correction letter. The labeling for the HeartMate II LVAS will be revised with the updated risk information related to percutaneous lead damage. Copies of this press release may be found on Thoratec’s website, www.thoratec.com, under Investor Relations/Press Releases.

Clinicians and patients with questions may contact the company at 1-800-528-2577, or if calling from outside the USA, 1-925-847-8600 (7 days a week, 8-5 Pacific Time).

FDA has been informed of this action.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
• Online: www.fda.gov/medwatch/report.htm
• Regular Mail: use postage-paid FDA form 3500 available at:
www.fda.gov/MedWatch/getforms.htm. Mail to MedWatch 5600 Fishers Lane, Rockville, MD
20852-9787
• Fax: 1-800-FDA-0178

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Problems with Boniva, Actonel & Fosamax

Many are taking Fosamax, Boniva and other similar drugs designed to stave off osteoporosis. Here's two articles we encourage you to read:

Fosamax, Boniva & Actonel Linked To Jaw Bone Disorders

http://injury-law.freeadvice.com/drug-toxic_chemicals/fosamax-linked-to-jaw-bone-disorders.htm

Merck Braces for Flood of Fosamax Lawsuits
Osteoporosis Medication Can Destroy Patients' Jawbones

http://www.consumeraffairs.com/news04/2007/02/fosamax.html